{
    "name": "phenylephrine ophthalmic",
    "comment": "Rx, OTC",
    "other_names": [
        "Altafrin",
        "Neofrin",
        "Refresh Redness Relief"
    ],
    "classes": [
        "Cycloplegics/Mydriatics",
        "Alpha Agonists",
        "Ophthalmic"
    ],
    "source": "https://reference.medscape.com/drug/altafrin-neofrin-phenylephrine-ophthalmic-343615",
    "pregnancy": {
        "common": [
            "Not known whether drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity; administer to a pregnant woman only if clearly needed"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Animal reproduction studies have not been conducted with topical phenylephrine"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "It is not known whether this drug is excreted in human breast milk; because many drugs are excreted in human milk, caution should be exercised when therapy is administered to a nursing woman"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity, narrow-angle glaucoma, ventricular tachycardia, hypertension"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Reduce dose if used within 21 d of MAO inhibitors or TCAs",
                "Wait 5 min between multiple drops (no >3 drops needed)",
                "Rebound miosis may occur in elderly people 1 day after treatmentwith phenylephrine",
                "Notify healthcare provider if vision changes, worsening of symptoms, or continued redness occur",
                "Caution with marked hypertension, cardiac disorders, advanced arteriosclerotic changes, type 1 diabetes mellitus, hyperthyroidism; in children of low body weight; elderly",
                "May cause false-normal tonometry readings, tonometry should be performed before phenylephrine is administered",
                "Presence of sulfites in some products may cause allergic reactions in susceptible patients"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid increases effects of phenylephrine ophthalmic by pharmacodynamic synergism. Use Caution/Monitor. Some systemic absorption of ophthalmic phenylephrine; reduce dose within 21 days of MAO inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "linezolid",
            "description": {
                "common": "linezolid increases effects of phenylephrine ophthalmic by pharmacodynamic synergism. Use Caution/Monitor. Some systemic absorption of ophthalmic phenylephrine; reduce dose within 21 days of MAO inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "lofepramine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine increases effects of phenylephrine ophthalmic by pharmacodynamic synergism. Use Caution/Monitor. Some systemic absorption of ophthalmic phenylephrine; reduce dose within 21 days of MAO inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine increases effects of phenylephrine ophthalmic by pharmacodynamic synergism. Use Caution/Monitor. Some systemic absorption of ophthalmic phenylephrine; reduce dose within 21 days of MAO inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine increases effects of phenylephrine ophthalmic by pharmacodynamic synergism. Use Caution/Monitor. Some systemic absorption of ophthalmic phenylephrine; reduce dose within 21 days of MAO inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "trimipramine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Frequent",
            "percent": null
        },
        {
            "name": "transient burning or stinging",
            "percent": null
        },
        {
            "name": "Arrhythmia",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "Subarachnoid hemorrhage",
            "percent": null
        },
        {
            "name": "Headache or browache",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Rebound myosis",
            "percent": null
        },
        {
            "name": "Reactive hyperemia",
            "percent": null
        },
        {
            "name": "Transient keratitis",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions such as allergic conjunctivitis or dermatitis",
            "percent": null
        },
        {
            "name": "Sensitivity to light",
            "percent": null
        }
    ]
}